The burden and management of cytochrome P450 2D6 (CYP2D6)‐mediated drug–drug interaction (DDI): co‐medication of metoprolol and paroxetine or fluoxetine in the elderly

Metoprolol and paroxetine/fluoxetine are inevitably co‐prescribed because cardiovascular disorders and depression often coexist in the elderly. This leads to CYP2D6‐mediated drug–drug interactions (DDI). Because systematic evaluations are lacking, we assessed the burden of metoprolol–paroxetine/fluoxetine interaction in the elderly and how these interactions are managed in Dutch community pharmacies.

[1]  Chii‐Ming Lee,et al.  Drug-related problems vary with medication category and treatment duration in Taiwanese heart failure outpatients receiving case management. , 2016, Journal of the Formosan Medical Association = Taiwan yi zhi.

[2]  Dave Brindamour,et al.  A metoprolol–terbinafine combination induced bradycardia , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[3]  Hao Wang,et al.  P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study , 2015, Drug Safety.

[4]  S. Vegter,et al.  Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design , 2015, Current medical research and opinion.

[5]  N. Stocks,et al.  The prevalence of co‐prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community‐dwelling elderly Australians , 2014, Journal of clinical pharmacy and therapeutics.

[6]  Supinya Dechanont,et al.  Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta‐analysis , 2014, Pharmacoepidemiology and drug safety.

[7]  H. Bos,et al.  Angiotensin-Converting Enzyme Inhibitor Treatment and the Development of Urinary Tract Infections: A Prescription Sequence Symmetry Analysis , 2013, Drug Safety.

[8]  E. Wiemer,et al.  Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen , 2013, Breast Cancer Research and Treatment.

[9]  B. Adams-Huet,et al.  Differential Effects of Nebivolol Versus Metoprolol on Functional Sympatholysis in Hypertensive Humans , 2013, Hypertension.

[10]  Rianne J. Zaal,et al.  Identification of drug-related problems by a clinical pharmacist in addition to computerized alerts , 2013, International Journal of Clinical Pharmacy.

[11]  M. Schwab,et al.  META-ANALYSIS OF CYP2D6 METABOLIZER PHENOTYPE AND METOPROLOL PHARMACOKINETICS , 2013, Clinical pharmacology and therapeutics.

[12]  C. Nemeroff,et al.  TREATMENT OF DEPRESSION IN CARDIOVASCULAR DISEASE , 2013, Depression and anxiety.

[13]  C. Tannenbaum,et al.  Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy , 2013, The Annals of pharmacotherapy.

[14]  T. Gomes,et al.  Antidepressants, metoprolol and the risk of bradycardia , 2012, Therapeutic advances in psychopharmacology.

[15]  B. Wiese,et al.  Age- and gender-specific prevalence of depression in latest-life--systematic review and meta-analysis. , 2012, Journal of affective disorders.

[16]  C. Tannenbaum,et al.  Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software. , 2011, The American journal of geriatric pharmacotherapy.

[17]  Sandra L Kane-Gill,et al.  A critical evaluation of clinical decision support for the detection of drug–drug interactions , 2011, Expert opinion on drug safety.

[18]  A. Scheen.  Cytochrome P450-mediated cardiovascular drug interactions , 2011, Expert opinion on drug metabolism & toxicology.

[19]  J. Soberman,et al.  Effects of Paroxetine on the Pharmacokinetics and Pharmacodynamics of Immediate‐Release and Extended‐Release Metoprolol , 2011, Pharmacotherapy.

[20]  R. Brook,et al.  Influence of Metoprolol Dosage Release Formulation on the Pharmacokinetic Drug Interaction With Paroxetine , 2011, Journal of clinical pharmacology.

[21]  R. Brook,et al.  The Impact of Paroxetine Coadministration on Stereospecific Carvedilol Pharmacokinetics , 2010, Journal of cardiovascular pharmacology and therapeutics.

[22]  B. Wettermark,et al.  Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. , 2010, British journal of clinical pharmacology.

[23]  K. Brøsen,et al.  Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol’s O-demethylation via CYP2D6 , 2010, European Journal of Clinical Pharmacology.

[24]  Marc Berg,et al.  Drug safety alert generation and overriding in a large Dutch university medical centre , 2009, Pharmacoepidemiology and drug safety.

[25]  Michelle Sweidan,et al.  Quality of drug interaction alerts in prescribing and dispensing software , 2009, The Medical journal of Australia.

[26]  U. Bergman,et al.  CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction , 2008, European Journal of Clinical Pharmacology.

[27]  Marc Berg,et al.  Research Paper: Turning Off Frequently Overridden Drug Alerts: Limited Opportunities for Doing It Safely , 2008, J. Am. Medical Informatics Assoc..

[28]  T. Wiersma,et al.  NHG houdt voorkeur voor metoprolol , 2008 .

[29]  B. Cumurcu,et al.  Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. , 2008, Mayo Clinic proceedings.

[30]  A. Hofman,et al.  Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. , 2008, British journal of clinical pharmacology.

[31]  U. Bergman,et al.  Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI) , 2008, European Journal of Clinical Pharmacology.

[32]  A. Egberts,et al.  Compliance with National Guidelines for the Management of Drug–Drug Interactions in Dutch Community Pharmacies , 2007, The Annals of pharmacotherapy.

[33]  Donna C. Dare,et al.  Reasons provided by prescribers when overriding drug-drug interaction alerts. , 2007, The American journal of managed care.

[34]  C. Meier,et al.  Management of drug‐interaction alerts in community pharmacies , 2007, Journal of clinical pharmacy and therapeutics.

[35]  Amanda L Golbeck,et al.  The Potential for Clinically Significant Drug-Drug Interactions Involving the CYP 2D6 System: Effects with Fluoxetine and Paroxetine versus Sertraline , 2007, Journal of psychiatric practice.

[36]  Marc Berg,et al.  Overriding of drug safety alerts in computerized physician order entry. , 2006, Journal of the American Medical Informatics Association : JAMIA.

[37]  J. Brouwers,et al.  Clinical Relevance of Drug-Drug Interactions , 2005, Drug safety.

[38]  A. Eggen,et al.  Co-prescription of cytochromeP450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies , 2005, European Journal of Clinical Pharmacology.

[39]  L. Lindholm,et al.  Atenolol in hypertension: is it a wise choice? , 2004, The Lancet.

[40]  S. Davies,et al.  Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. , 2004, British journal of clinical pharmacology.

[41]  H. Kroemer,et al.  Drug-Drug Interactions of β-Adrenoceptor Blockers , 2003, Arzneimittelforschung.

[42]  Roger B. Davis,et al.  Physicians' decisions to override computerized drug alerts in primary care. , 2003, Archives of internal medicine.

[43]  C. O'connor,et al.  Depression and cardiovascular disease: mechanisms of interaction , 2003, Biological Psychiatry.

[44]  Michael Böhm,et al.  Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects , 2002, Clinical pharmacology and therapeutics.

[45]  L. de Jong-van den Berg,et al.  Pharmacy data in epidemiological studies: an easy to obtain and reliable tool , 2002, Pharmacoepidemiology and drug safety.

[46]  G. Thorgeirsson,et al.  Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. , 2002, Journal of cardiac failure.

[47]  B. Fagerberg,et al.  Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. , 2001, Journal of the American College of Cardiology.

[48]  M. Maes,et al.  Depression and myocardial infarction: relationship between heart and mind , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[49]  S. Preskorn,et al.  The economic consequences of a drug-drug interaction. , 2001, Journal of clinical psychopharmacology.

[50]  R. Lefebvre,et al.  Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers , 2000, Clinical pharmacology and therapeutics.

[51]  L. Ereshefsky,et al.  CYP2D6 Inhibition by Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in a Crossover Study: Intraindividual Variability and Plasma Concentration Correlations , 2000, Journal of clinical pharmacology.

[52]  L. Ereshefsky,et al.  CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. , 1999, Journal of clinical psychopharmacology.

[53]  S. Wössner,et al.  [Bradycardia after beginning therapy with metoprolol and paroxetine]. , 1996, Psychiatrische Praxis.

[54]  J. Doucet,et al.  Drug‐Drug Interactions Related to Hospital Admissions in Older Adults: A Prospective Study of 1000 Patients , 1996, Journal of the American Geriatrics Society.

[55]  M. Pirmohamed,et al.  Interaction of metoprolol and fluoxetine , 1993, The Lancet.

[56]  G. Schettler,et al.  Cardiovascular Drug Therapy in the Elderly , 1988, Developments in Cardiovascular Medicine.

[57]  I. Radić,et al.  Quality of life of elderly people living in a retirement home. , 2016, Vojnosanitetski pregled.

[58]  T. Egberts,et al.  Pharmacist-Based Medication Review Reduces Potential Drug-Related Problems in the Elderly , 2009, Drugs & aging.

[59]  E. García Vicente,et al.  [Post-myocardial infarction depression]. , 2007, Anales de medicina interna.

[60]  D. Veale,et al.  National Collaborating Centre for Mental Health , 2006 .

[61]  Robyn Tamblyn,et al.  Reasons for Physician Non-Adherence to Electronic Drug Alerts , 2004, MedInfo.

[62]  H. Kroemer,et al.  Drug-drug interactions of beta-adrenoceptor blockers. , 2003, Arzneimittel-Forschung.

[63]  S. Loft,et al.  Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine , 1996, European Journal of Clinical Pharmacology.